




## 2022 AGM AGENDA

#	Agenda Item	Time Allocated	Planned End Time
	<b>Procedural/Consent Items</b>		
1	Call to Order: K. Morrison	9:15 am	9:16 am
2	Introductions and Welcome Remarks: K. Morrison	9:16 am	9:20 am
3	Approval of AGM Agenda and Call for Other Business: K. Morrison	9:20 am	9:21 am
4	Declarations of Conflict of Interest: K. Morrison	9:21 am	9:23 am
5	<b>Minutes of January 13, 2023 AGM: K. Morrison</b> <ul style="list-style-type: none"> <li>• Motion to accept the AGM minutes of January 13, 2023</li> </ul>	9:23 am	9:25 am
6	<b>Treasurer's Report: V. Pringle</b> <ul style="list-style-type: none"> <li>• CPFF FY 22-23 audited financial statements: N. Jilani, V. Pringle &amp; S. Lee               <ul style="list-style-type: none"> <li>○ <b>Motion to accept the 2022/2023 Audited Statements</b></li> </ul> </li> <li>• Appointment of auditors for the 2023/2024 fiscal year: V. Pringle               <ul style="list-style-type: none"> <li>○ <b>Motion to appoint Schwartz Levitsky Feldman LLP, Chartered Accounts as auditors for the 2023/20224 fiscal year</b></li> </ul> </li> </ul>	9:25 am	9:30 am
7	<b>Governance: T. Georgieff</b> <ul style="list-style-type: none"> <li>• Election of the Board of Directors               <ul style="list-style-type: none"> <li>○ Motion to accept the                   <ul style="list-style-type: none"> <li>▪ Confirmation of CPFF Directors</li> <li>▪ Election/Appointment of CPFF Directors</li> <li>▪ Confirmation of CPFF Committee Chairs</li> </ul> </li> </ul> </li> </ul>	9:30 am	9:40 am
8	<b>Other Business</b>	9:40 am	9:45 am
9	<b>Adjournment</b>		
10	<b>Next AGM Meeting TBD</b>		



# Canadian Pulmonary Fibrosis Foundation

**AGM Minutes  
Held via ZOOM  
On Friday January 13, 2023  
Commencing at 3:00 pm EST**

**Present:** Kirk Morrison, Chair  
Moyra Martin, Vice & Governance Chair  
Verity Pringle, Treasurer  
Sharon Lee, Executive Director  
Todd Georgieff, Communications & Fundraising Co-Chair  
Mark Ashcroft, Advocacy & Support Co-Chair (joined @ 3:08pm)  
Nicole Hilliard  
Derek Mastin (joined @ 3:08pm)  
Ray Protti  
Dr. Gokul Vidyasankar

**Guest(s):** Dr. Charlene Fell

**Regrets:** Dr. Holly Smith, Advocacy & Support Co-Chair  
Tom Hunter, Communications & Fundraising Co-Chair  
Ranjena Maloni

**Minutes:** Roberto Zapata

**1. Call to Order**

The AGM was called to order by K. Morrison.

**2. Introductions and Welcome**

K. Morrison welcomed everyone.

**3. Approval of the AGM Agenda**

It was moved and seconded,

**That the AGM agenda be approved.**

**Carried.**

**4. Declarations of Conflict of Interest**

There were no declarations of conflict.

**5. Minutes of January 14, 2022 AGM**

It was moved and seconded,

**That the minutes of the January 14, 2022 AGM be approved.**

**Carried.**

**6. Treasure's Report**

The Treasurer presented the Audited Financial Statement for the year ending July 31, 2022 and made a recommendation for the appointment of the auditors for the 2022/2023 fiscal year.

It was moved and seconded,

**That the audited financial statements for the 2021/2022 fiscal year be approved.**

**Carried.**

It was moved and seconded,

**That Schwartz Levitsky Feldman LLP, Chartered Accounts be approved as auditors for the 2022/2023 fiscal year.**

**Carried.**

**7. Governance's Report**

Election of the Board of Directors, Officers and Committee Chairs

1. Acceptance of the Resignations of CPFF Director Dr. Gokul Vidyasankar and CPFF Director and Vice-Chair Moyra Martin. We express our deep gratitude for their contributions to CPFF and thank them for their commitment, passion and service to all those affected by Pulmonary Fibrosis.
2. CPFF approved Winston Fiander and Peter Kleinstiver as CPFF Directors in the fall 2022; However, CPFF lost these two members when Peter passed away suddenly and Winston resigned due to poor health. Their interest and desire to be involved will be remembered.
3. Confirmation of the following CPFF Directors
  - Kirk Morrison confirmed for the third year of a second 'three-year' term.
  - Verity Pringle confirmed for the third year of a first 'three-year' term.
  - Todd Georgieff confirmed for the first year of a second 'three-year' term.
  - Tom Hunter confirmed for the first year of a second 'three-year' term.
  - Ranjena Maloni confirmed for the third year of a second 'three-year' term.
  - Holly Smith appointed for the second year of a 'three-year' term.
  - Ray Protti appointed for the second year of a 'three-year' term.
  - Mark Ashcroft appointed for the second year of a 'three-year' term.
4. Election/Appointment of CPFF Directors  
A motion to appoint the following CPFF Directors to a three-year term as CPFF Board of Directors

## CPFF AGM Minutes of January 13, 2023

- Derek Mastin appointed CPFF Director for the first year of a 'three-year' term.
  - Nicole Hilliard appointed CPFF Director for the first year of a 'three-year' term.
5. A motion to appoint said officers of CPFF for the 2023/2024 year.
- Chairperson - Kirk Morrison
  - Vice-Chairperson - Todd Georgieff
  - Treasurer - Verity Pringle
6. Secretary - Confirmation that Sharon Lee, Executive Director, CPFF (Ex-Officio) will continue as interim Secretary for the CPFF Board of Directors until a Director is appointed.
7. Confirmation of CPFF Committee Chairs
- Communications and Fundraising Committee - Tom Hunter
  - Support and Advocacy Committee - Mark Ashcroft and Holly Smith
  - Governance and Finance Committee - Todd Georgieff
  - Medical Advisory Board - Dr. Charlene Fell
  - Medical Advisory Board Director Liaison – Vacant

It was moved and seconded,

**That the above motions be approved as presented.**

**Carried.**

### **8. Other Business**

There was no other new business.

### **9. Adjournment**

There being no further business the meeting was adjourned.

Next CPFF AGM Meeting will be determined.

Certified correct,

### **SIGNATURE TO BE INCLUDED**

Kirk Morrison  
CPFF Board Chair

**CANADIAN PULMONARY FIBROSIS FOUNDATION**

**FINANCIAL STATEMENTS**

**JULY 31, 2023**

"DRAFT - for discussion only"

# **CANADIAN PULMONARY FIBROSIS FOUNDATION**

## **FINANCIAL STATEMENTS**

**JULY 31, 2023**

### **TABLE OF CONTENTS**

Independent Auditor's Report	1 - 3
Statement of Financial Position	4
Statement of Operations	5
Statement of Changes in Net Assets	6
Statement of Cash Flows	7
Notes to Financial Statements	8 - 12

## INDEPENDENT AUDITOR'S REPORT

To the Directors of  
Canadian Pulmonary Fibrosis Foundation

### Report on the Audit of the Financial Statements

#### Qualified Opinion

We have audited the financial statements of Canadian Pulmonary Fibrosis Foundation (the "Organization"), which comprise the statement of financial position as at July 31, 2023, and the statements of operations, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at July 31, 2023, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

#### Basis for Qualified Opinion

In common with many not-for-profit organizations, the Organization derives revenue from donations and fundraising activities, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Organization. Therefore, we were not able to determine whether any adjustments might be necessary to donations and fundraising revenue, excess of revenue over expenses, and cash flows from operations for the years ended July 31, 2023 and 2022, current assets and liabilities as at July 31, 2023 and 2022, and net assets as at and July 31 for both the 2023 and 2022 years. Our audit opinion on the financial statements for the year ended July 31, 2022 was modified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

## INDEPENDENT AUDITOR'S REPORT (cont'd)

### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the organization or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- ♦ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ♦ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.



## INDEPENDENT AUDITOR'S REPORT (cont'd)

- ♦ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- ♦ Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- ♦ Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Report on Other Legal and Regulatory Requirements

As required by the Corporations Act (Ontario), we report that, in our opinion, the accounting policies applied in preparing and presenting the financial statements in accordance with Canadian accounting standards for not-for-profit organizations have been applied on a basis consistent with that of the preceding year.

Toronto, Ontario  
Date to be determined

Chartered Professional Accountants  
Licensed Public Accountants

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Statement of Financial Position

As at July 31, 2023

	2023	2022
<b>ASSETS</b>		
<b>CURRENT</b>		
Cash	\$ 1,448,147	\$ 1,196,659
Externally restricted cash (note 3)	81,800	270,000
Short-term investments	603,829	509,450
Government remittances recoverable	52,397	14,034
Prepaid expenses	3,002	1,621
	<b>\$ 2,189,175</b>	<b>\$ 1,991,764</b>
<b>LIABILITIES</b>		
<b>CURRENT</b>		
Accounts payable and accrued liabilities	\$ 40,016	\$ 106,144
Deferred revenue (note 3)	81,800	270,000
	<b>121,816</b>	<b>376,144</b>
<b>NET ASSETS</b>		
Unrestricted	2,067,359	1,615,620
	<b>\$ 2,189,175</b>	<b>\$ 1,991,764</b>

On behalf of the Organization

\_\_\_\_\_  
Director

\_\_\_\_\_  
Director

The accompanying notes are an integral part of these financial statements.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Statement of Operations

For the year ended July 31, 2023

	2023	2022
<b>REVENUE</b>		
Donations and fundraising	\$ 896,176	\$ 333,107
Foundation grants (note 3)	402,600	612,667
Interest income	20,705	1,083
Consulting fees	3,040	-
	<b>1,322,521</b>	<b>946,857</b>
<b>CHARITABLE EXPENSES</b>		
Awareness and advocacy	229,371	180,887
Patient support	163,535	195,779
Program education and consulting	120,973	101,299
Fellowship and research grants to institutions	180,000	270,000
Support website costs	47,269	39,403
Fundraising event costs	8,609	-
	<b>749,757</b>	<b>787,368</b>
<b>EXCESS OF REVENUE OVER CHARITABLE EXPENSES</b>	<b>572,764</b>	<b>159,489</b>
<b>ADMINISTRATIVE EXPENSES</b>		
Office and general	36,438	24,010
Professional fees	29,262	18,004
Salaries and benefits	25,282	22,669
Travel and meeting costs	14,132	36
Telephone	8,489	7,225
Interest and bank charges	4,004	9,249
Insurance	3,418	3,813
	<b>121,025</b>	<b>85,006</b>
<b>EXCESS OF REVENUE OVER EXPENSES</b>	<b>\$ 451,739</b>	<b>\$ 74,483</b>

The accompanying notes are an integral part of these financial statements.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Statement of Changes in Net Assets

For the year ended July 31, 2023

	Unrestricted	Total 2023	Total 2022
<b>BALANCE, BEGINNING OF YEAR</b>	\$ 1,615,620	\$ 1,615,620	\$ 1,541,137
Excess of revenue over expenses	451,739	451,739	74,483
<b>BALANCE, END OF YEAR</b>	<b>\$ 2,067,359</b>	<b>\$ 2,067,359</b>	<b>\$ 1,615,620</b>

"DRAFT - for discussion only"

The accompanying notes are an integral part of these financial statements.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Statement of Cash Flows

For the year ended July 31, 2023

	2023	2022
<b>OPERATING ACTIVITIES</b>		
Excess of revenue over expenses	\$ 451,739	\$ 74,483
Change in non-cash working capital items:		
Decrease in inventory	-	1,750
Increase in government remittances recoverable	(38,363)	(1,200)
Increase in prepaid expenses	(1,381)	-
Increase (decrease) in accounts payable and accrued liabilities	(66,128)	9,016
Increase (decrease) in deferred revenue	(188,200)	140,000
	157,667	224,049
<b>INVESTING ACTIVITIES</b>		
Decrease (increase) in externally restricted cash	188,200	(140,000)
Decrease in internally restricted cash	-	6,027
Increase in short-term investments	(94,379)	(57,432)
	93,821	(191,405)
<b>NET INCREASE IN CASH, DURING THE YEAR</b>	251,488	32,644
<b>CASH, BEGINNING OF YEAR</b>	1,196,659	1,164,015
<b>CASH, END OF YEAR</b>	\$ 1,448,147	\$ 1,196,659

The accompanying notes are an integral part of these financial statements.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Notes to Financial Statements

July 31, 2023

---

### 1. PURPOSE OF THE ORGANIZATION

The Canadian Pulmonary Fibrosis Foundation (“CPFF” or the “Organization”) is a not-for-profit organization incorporated on August 19, 2009 under the laws of Ontario without share capital for the purposes of raising funds for research into the causes and possible treatment of pulmonary fibrosis and to provide support to those suffering from the disease and their families. CPFF received registered charity status under the Income Tax Act on November 9, 2009 and is exempt from income taxes.

CPFF raises funds by various means including soliciting direct gifts from the public, corporate sponsorships/grants and various fund-raising events as may be approved from time to time. The funds so raised are used to support the Vision and Mission of the Organization.

The CPFF Vision statement is:

Creating hope and giving a voice to the pulmonary fibrosis community.

The Organization’s Mission statement is:

- Educate and raise awareness
- Support patients and caregivers
- Support research that benefits patients
- Give a voice to patients

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The financial statements have been prepared in accordance with Canadian Accounting Standards for Not-for-Profit Organizations (“ASNPO”) and are in accordance with Canadian generally accepted accounting principles. The significant accounting policies set out below have been applied in the preparation of the Organization’s financial statements for July 31, 2023 and have been applied on a basis consistent with that of the previous year.

#### (a) Revenue Recognition

The Organization follows the deferral method of accounting for contributions. Under this method, unrestricted contributions from donations are recognized as revenue in the current period in unrestricted net assets and restricted contributions are deferred and recognized as revenue in the period the related expenses are incurred in restricted net assets.

Fundraising revenue is recognized when events are completed and revenue is received or receivable.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Notes to Financial Statements

July 31, 2023

---

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)

#### (a) Revenue Recognition (cont'd)

Foundation grants are recognized as revenue in the period the grants are received or receivable provided the terms and conditions of the grants are complied with.

Stock donations are recognized when the fair value can be reasonably estimated either using the market or appraisal values at the date of the donation.

Interest income is recorded in the statement of operations when earned.

Consulting fees are earned for providing services under a consulting services agreement and are recognized on an accrual basis when services are performed.

#### (b) Short-term Investments

Short-term investments consist of funds invested in high-interest money market. These investments are classified as current assets due their reasonably prompt liquidity.

#### (c) Contributed Materials and Services

From time to time, volunteers contribute their services to the Organization's programs and activities. Since these services are not normally purchased by the Organization and due to the difficulty in determining and measuring the fair value of such services, they are not recognized in these financial statements.

#### (d) Measurement of Financial Instruments

The Organization initially measures its financial assets and liabilities originated or exchanged in arm's length transactions at fair value.

Subsequently, the Organization measures all its financial assets and financial liabilities at cost or amortized cost, except for investments in equity instruments that are quoted in an active market, which are measured at fair value. Changes in fair value of equity instruments are recognized in income in the period the change occurred.

Financial assets measured at amortized cost include short-term investments and cash.

Financial liabilities measured at amortized cost include accounts payable and accrued liabilities.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Notes to Financial Statements

July 31, 2023

---

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)

#### (e) Use of Estimates

The preparation of financial statements in conformity with ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Significant items requiring estimates and assumptions include the fair value of stock donations and recording of accrued liabilities. These estimates are reviewed periodically and adjustments made to income in the period such adjustments occur.

#### (f) Allocated Expenses

The Organization allocates certain expenses to various pillars as identified in the Organization's mission statement. The percentage allocation is in the same proportion as the allocation of grants revenue set by the Board of Directors, based on the time and hours spent on each pillar.

### 3. EXTERNALLY RESTRICTED CASH AND DEFERRED REVENUE

Externally restricted cash represents unutilized grants. During the year, the Organization received a grant of \$46,800 from one of the pharmaceutical companies for the purpose of developing an Indigenous Patient Story of which the unspent amount of \$31,800 was deferred at year-end.

The Organization had also received \$150,000 during the year ended July 31, 2022 for researchers to write a research paper of which the unspent amount of \$50,000 was deferred at year-end.

	2023	2022
Deferred revenue, beginning of year	\$ 270,000	\$ 130,000
Received in the year	214,400	752,667
Recognized as revenue for expenses incurred	(402,600)	(612,667)
Balance, end of year	\$ 81,800	\$ 270,000



# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Notes to Financial Statements

July 31, 2023

---

### 4. FINANCIAL INSTRUMENTS

#### Risks and Concentrations

The Organization is exposed to various risks through its financial instruments. The following analysis provides a measure of the Organization's risk exposure and concentrations at July 31, 2023 which did not change significantly from the previous period unless otherwise noted.

#### Liquidity Risk

Liquidity risk is the risk that the Organization will not be able to meet its financial obligation as they become due. CPFF is exposed to this risk mainly in respect of its accounts payable and accrued liabilities and unutilized grants totaling \$81,800. The Organization believes the exposure was not significant at the year-end.

#### Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Organization is primarily exposed to credit risk from its cash and short-term investments held at two financial institutions. The Organization's banks are established reputable financial institutions in Canada and therefore believes this risk is not significant.

#### Market Risk

Market risk is the risk that the fair value or future cash flows of the Organization's financial instruments will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. The Organization is mainly exposed to interest rate risk. The Organization does not use derivative financial instruments to reduce its exposure to this risk.

#### Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. At the year-end, the Organization held high interest money market funds which subjects the Organization to a fair value risk. Management does not consider this risk to be significant given the Organization's sound financial position.

# CANADIAN PULMONARY FIBROSIS FOUNDATION

## Notes to Financial Statements

July 31, 2023


### 5. ALLOCATION OF EXPENSES BY FUNCTION

The Organization allocates salaries and consulting expenses to various pillars as identified in the Organization's mission statement.

The percentage allocation is in the same proportion as the allocation of grants revenue set by the Board of Directors, based on the time and hours spent on each pillar

	2023 (%)	2022 (%)
In Percentages:		
Awareness and advocacy	40	40
Patient support	23	23
Program education and consulting	23	23
General and administrative	14	14
	100	100

	2023	2022
Awareness and advocacy	\$ 205,529	\$ 175,993
Patient support	118,179	101,196
Program education and consulting	118,179	101,196
General and administrative	71,935	61,598
	\$ 513,822	\$ 439,983



# Canadian Pulmonary Fibrosis Foundation

*Breathing should never be hard work* ©


To: CPFF Members  
From: Todd Georgieff, Chair of Governance and Finance Committee  
Date: January 25, 2024  
Subject: Board Terms & Appointments

---

#### **Committee Members:**

Todd Georgieff, Vice Chair  
Kirk Morrison, Board Chair  
Verity Pringle, Treasurer  
Ray Protti, Director  
Ranjena Maloni, Director  
Sharon Lee, Executive Director, Ex-officio


1. Acceptance of the Resignation of CPFF Director, Ranjena Maloni. We extend our sincere appreciation for her dedicated contributions, passion, and service to all individuals affected by pulmonary fibrosis.
2. Confirmation of the following CPFF Directors
  - Kirk Morrison confirmed for the first year of a third “three-year” term.
  - Verity Pringle confirmed for the first year of a second “three-year” term.
  - Todd Georgieff confirmed for the second year of a second “three-year” term.
  - Tom Hunter confirmed for the second year of a second “three-year” term.
  - Holly Smith confirmed for the third year of a first “three-year” term.
  - Ray Protti confirmed for the third year of a first “three-year” term.
  - Mark Ashcroft confirmed for the third year of a first “three-year” term.
  - Nicole Hilliard confirmed for the second year of a first “three-year” term.
  - Derek James confirmed for the second year of a first “three-year” term.
3. A motion to appoint said officers of CPFF for the 2023/2024 year.
  - Chairperson - Todd Georgieff
  - Vice Chair - TBD
  - Treasurer – Verity Pringle
4. Secretary – Confirmation that Sharon Lee, Executive Director, PFF (Ex-Officio) will continue as interim Secretary for the CPFF Board of Directors until a Director is appointed.
5. Confirmation of CPFF Committee Chairs
  - Communications and Fundraising Committee – Tom Hunter
  - Advocacy and Support Committee – Mark Ashcroft and Holly Smith
  - Governance and Finance Committee – Todd Georgieff
  - Medical Advisory Board – Dr. Charlene Fell
  - Medical Advisory Board Director Liaison - TBD



# Canadian Pulmonary Fibrosis Foundation

*Breathing should never be hard work* ©

	Start Date	Term 1	Term 2	Term 3
<b>Mark Ashcroft</b>	Jan, 8 2021	21-22 22-23 *23-24		
<b>Todd Georgieff</b>	Jan. 2019	19-20 20-21 21-22	22-23 *23-24	
<b>Nicole Hilliard</b>	Jan. 13, 2022	22-23 *23-24		
<b>Tom Hunter</b>	Jan. 2019	19-20 20-21 21-22	22-23 *23-24	
<b>Derek James</b>	Jan. 13, 2022	22-23 *23-24		
<b>Kirk Morrison</b>	Jan. 2017	17-18 18-19 19-20	20-21 21-22 22-23	*23-24
<b>Verity Pringle</b>	Jan. 2020	20-21 21-22 22-23	*23-24	
<b>Ray Protti</b>	Jan. 8, 2021	21-22 22-23 *23-24		
<b>Holly Smith</b>	Jan 8, 2021	21-22 22-23 *23-24		



# Canadian Pulmonary Fibrosis Foundation

*Breathing should never be hard work* ©

	Start Date	Term 1	Term 2	Term 3
CPFF Past Board Directors				
<b>Ranjena Maloni</b>	Nov. 2017	17-18 18-19 19-20	20-21 21-22 22-23	
<b>Dr. Gokul Vidyasankar</b>	Nov. 2017	17-18 18-19 19-20	20-21 21-22 *22-23	
<b>Robert Davidson</b>	2009			
<b>Heather Davidson</b>	2009			
<b>Mark Davidson</b>	2009			
<b>Matthew Davidson</b>	2009			
<b>Winston Fiander</b>	Jan. 13, 2022	*22-23		
<b>Peter Kleinster</b>	Jan. 13, 2022	*22-23 Passed Away		
<b>Barbara Barr</b>	2013			
<b>George Kaminsky</b>	Jan. 2014			
<b>Doug Barber</b>	Jan. 2015			
<b>Darlene Gallant</b>	Jan. 2015			
<b>Stephen Binch</b>	Nov. 2017			
<b>Pat Popwell</b>	Nov. 2017			
<b>Moyra Martin</b>	Jan. 2014	14-15 15-16 17-18 18-19	18-19 19-20 20-21	21-22 *22-23